Icatibant (Firazyr®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000344
English
Authors' recommendations:
Icatibant (Firazyr®) is recommended as an option for use within NHS Wales for the symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1 esterase inhibitor deficiency).
This recommendation applies only in circumstances where the approved Wales patient access scheme is utilised.
AWMSG is of the opinion that icatibant (Firazyr®) is suitable for specialist only prescribing within NHS Wales for the above indication.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=187460&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Angioedemas, Hereditary
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.